Shopping Cart 0
Cart Subtotal
USD 0

Novo Nordisk AS (NOVO B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company's product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products, hormone replacement therapy and other serious chronic diseases. With subsidiaries in Europe, North America, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS (NOVO B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16

Venture Financing 18

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18

Partnerships 20

Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20

Ossianix and Novo Nordisk Enter into Research and Option Agreement 21

Evotec Enters into Co-Development Agreement with Novo Nordisk 22

Kallyope and Novo Nordisk Enter into Research Agreement 23

BioLamina and Novo Nordisk Enter into Partnership 24

Prime Therapeutics Enters into Contract with Novo Nordisk 25

Metacrine Enters into Agreement with Novo Nordisk 26

Novo Nordisk Enters into Research Agreement with University of Oxford 27

Novo Nordisk Enters into Research Agreement with UW Medicine 28

BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29

Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30

Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31

Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32

Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33

Licensing Agreements 34

Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34

Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35

Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36

Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37

Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38

Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39

Novo Nordisk Enters Licensing Agreement into with reMYND 40

Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41

Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42

Novo Nordisk Enters into Licensing Agreement with Ablynx 43

Novo Nordisk Enters into Licensing Agreement with Emisphere 44

Novo Nordisk Expands Licensing Agreement with Genmab 45

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46

Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47

Novo Nordisk Amends Licensing Agreement with Emisphere 48

Adimab Enters Into Licensing Agreement With Novo Nordisk 49

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50

Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51

Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52

Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53

Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55

Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56

Equity Offering 57

Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57

NNIT Prices IPO for USD191 Million 58

Asset Transactions 60

Novo Nordisk Plans to Sell Inflammation Business 60

Acquisition 61

Novo Nordisk May Acquire Global Blood Therapeutics 61

Novo Nordisk to Acquire Calibrium and MB2 62

Novo Nordisk AS-Key Competitors 63

Novo Nordisk AS-Key Employees 64

Novo Nordisk AS-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Recent Developments 70

Strategy And Business Planning 70

Nov 01, 2018: Novo Nordisk to buy rights to Strongbridge's Macrilen for USD 145m 70

Oct 01, 2018: Novo Nordisk to establish California manufacturing site for stem cell-based therapies 71

Sep 12, 2018: Novo Nordisk research centre opens in Oxford 12 Sep 2018 72

May 16, 2018: Novo Nordisk increases commitment to stem cell-based therapies 74

Feb 12, 2018: Novo Nordisk Plans USD 65M Expansion of Clayton Manufacturing Site 75

Financial Announcements 76

Nov 01, 2018: Novo Nordisk''s operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018 76

May 02, 2018: Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 77

Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) 78

Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 79

Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 80

May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 81

Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 82

Corporate Communications 83

Oct 15, 2018: Novo Nordisk names Ludovic Helfgott executive vice president Biopharm 83

Sep 20, 2018: Novo Nordisk to lay off 400 employees in Denmark and China 84

May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 85

May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 86

Legal and Regulatory 87

Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives 87

Government and Public Interest 88

Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 88

May 01, 2018: Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes 90

Oct 31, 2017: New US study reveals key reasons why millions of people with obesity are not receiving adequate care 91

Jun 07, 2017: Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management 92

Apr 17, 2017: Novo Nordisk Foundation Grant 93

Product News 94

12/15/2017: Ozempic (semaglutide) recommended for approval by the European regulatory authorities 94

Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System 95

12/05/2017: Ozempic (semaglutide) approved in the US 96

10/18/2017: Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide 97

09/12/2017: More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments 98

08/28/2018: Novo Nordisk reports positive results from SUSTAIN 6 trial 99

03/23/2018: Ozempic approved in Japan for the treatment of type 2 diabetes 100

03/20/2018: New diabetes drug may help people with obesity lose weight 101

03/05/2018: OZEMPIC now available for Canadians with type 2 diabetes 102

02/09/2018: Novo Nordisk: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes 103

02/05/2018: Novo Nordisk Launches Ozempic Expanding Treatment Options for Adults with Diabetes 104

Product Approvals 105

Oct 16, 2017: Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide 105

Feb 28, 2017: Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan 106

Clinical Trials 108

Jun 23, 2018: Ozempic Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis 108

Feb 01, 2018: Semaglutide demonstrated significant reductions in blood sugar and weight compared with dulaglutide; results published in The Lancet Diabetes & Endocrinology 109

Jan 09, 2018: Ozempic approved in Canada for the treatment of adults with type 2 diabetes 110

Aug 16, 2017: Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 112

Apr 03, 2017: Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment 113

Other Significant Developments 114

Nov 02, 2018: Novo Nordisk to lay off 1,300 employees 114

Aug 08, 2018: Novo Nordisk's operating profit decreased by 8% in danish kroner and increased by 4% in local currencies in the first six months of 2018 115

Mar 16, 2017: CVS Health Launches Reduced Rx Savings Program to Give Patients Access to More Affordable Medications 116

Appendix 117

Methodology 117

About GlobalData 117

Contact Us 117

Disclaimer 117


List Of Figure

List of Figures

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Novo Nordisk AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Novo Nordisk AS, Deals By Therapy Area, 2012 to YTD 2018 11

Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18

Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20

Ossianix and Novo Nordisk Enter into Research and Option Agreement 21

Evotec Enters into Co-Development Agreement with Novo Nordisk 22

Kallyope and Novo Nordisk Enter into Research Agreement 23

BioLamina and Novo Nordisk Enter into Partnership 24

Prime Therapeutics Enters into Contract with Novo Nordisk 25

Metacrine Enters into Agreement with Novo Nordisk 26

Novo Nordisk Enters into Research Agreement with University of Oxford 27

Novo Nordisk Enters into Research Agreement with UW Medicine 28

BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29

Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30

Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31

Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32

Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33

Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34

Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35

Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36

Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37

Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38

Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39

Novo Nordisk Enters Licensing Agreement into with reMYND 40

Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41

Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42

Novo Nordisk Enters into Licensing Agreement with Ablynx 43

Novo Nordisk Enters into Licensing Agreement with Emisphere 44

Novo Nordisk Expands Licensing Agreement with Genmab 45

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46

Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47

Novo Nordisk Amends Licensing Agreement with Emisphere 48

Adimab Enters Into Licensing Agreement With Novo Nordisk 49

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50

Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51

Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52

Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53

Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55

Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56

Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57

NNIT Prices IPO for USD191 Million 58

Novo Nordisk Plans to Sell Inflammation Business 60

Novo Nordisk May Acquire Global Blood Therapeutics 61

Novo Nordisk to Acquire Calibrium and MB2 62

Novo Nordisk AS, Key Competitors 63

Novo Nordisk AS, Key Employees 64

Novo Nordisk AS, Subsidiaries 65

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Novo Nordisk AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company's product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products, hormone replacement therapy and other serious chronic diseases. With subsidiaries in Europe, North America, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS (NOVO B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16

Venture Financing 18

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18

Partnerships 20

Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20

Ossianix and Novo Nordisk Enter into Research and Option Agreement 21

Evotec Enters into Co-Development Agreement with Novo Nordisk 22

Kallyope and Novo Nordisk Enter into Research Agreement 23

BioLamina and Novo Nordisk Enter into Partnership 24

Prime Therapeutics Enters into Contract with Novo Nordisk 25

Metacrine Enters into Agreement with Novo Nordisk 26

Novo Nordisk Enters into Research Agreement with University of Oxford 27

Novo Nordisk Enters into Research Agreement with UW Medicine 28

BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29

Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30

Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31

Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32

Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33

Licensing Agreements 34

Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34

Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35

Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36

Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37

Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38

Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39

Novo Nordisk Enters Licensing Agreement into with reMYND 40

Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41

Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42

Novo Nordisk Enters into Licensing Agreement with Ablynx 43

Novo Nordisk Enters into Licensing Agreement with Emisphere 44

Novo Nordisk Expands Licensing Agreement with Genmab 45

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46

Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47

Novo Nordisk Amends Licensing Agreement with Emisphere 48

Adimab Enters Into Licensing Agreement With Novo Nordisk 49

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50

Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51

Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52

Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53

Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55

Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56

Equity Offering 57

Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57

NNIT Prices IPO for USD191 Million 58

Asset Transactions 60

Novo Nordisk Plans to Sell Inflammation Business 60

Acquisition 61

Novo Nordisk May Acquire Global Blood Therapeutics 61

Novo Nordisk to Acquire Calibrium and MB2 62

Novo Nordisk AS-Key Competitors 63

Novo Nordisk AS-Key Employees 64

Novo Nordisk AS-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Recent Developments 70

Strategy And Business Planning 70

Nov 01, 2018: Novo Nordisk to buy rights to Strongbridge's Macrilen for USD 145m 70

Oct 01, 2018: Novo Nordisk to establish California manufacturing site for stem cell-based therapies 71

Sep 12, 2018: Novo Nordisk research centre opens in Oxford 12 Sep 2018 72

May 16, 2018: Novo Nordisk increases commitment to stem cell-based therapies 74

Feb 12, 2018: Novo Nordisk Plans USD 65M Expansion of Clayton Manufacturing Site 75

Financial Announcements 76

Nov 01, 2018: Novo Nordisk''s operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018 76

May 02, 2018: Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 77

Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) 78

Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 79

Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 80

May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 81

Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 82

Corporate Communications 83

Oct 15, 2018: Novo Nordisk names Ludovic Helfgott executive vice president Biopharm 83

Sep 20, 2018: Novo Nordisk to lay off 400 employees in Denmark and China 84

May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 85

May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 86

Legal and Regulatory 87

Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives 87

Government and Public Interest 88

Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 88

May 01, 2018: Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes 90

Oct 31, 2017: New US study reveals key reasons why millions of people with obesity are not receiving adequate care 91

Jun 07, 2017: Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management 92

Apr 17, 2017: Novo Nordisk Foundation Grant 93

Product News 94

12/15/2017: Ozempic (semaglutide) recommended for approval by the European regulatory authorities 94

Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System 95

12/05/2017: Ozempic (semaglutide) approved in the US 96

10/18/2017: Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide 97

09/12/2017: More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments 98

08/28/2018: Novo Nordisk reports positive results from SUSTAIN 6 trial 99

03/23/2018: Ozempic approved in Japan for the treatment of type 2 diabetes 100

03/20/2018: New diabetes drug may help people with obesity lose weight 101

03/05/2018: OZEMPIC now available for Canadians with type 2 diabetes 102

02/09/2018: Novo Nordisk: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes 103

02/05/2018: Novo Nordisk Launches Ozempic Expanding Treatment Options for Adults with Diabetes 104

Product Approvals 105

Oct 16, 2017: Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide 105

Feb 28, 2017: Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan 106

Clinical Trials 108

Jun 23, 2018: Ozempic Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis 108

Feb 01, 2018: Semaglutide demonstrated significant reductions in blood sugar and weight compared with dulaglutide; results published in The Lancet Diabetes & Endocrinology 109

Jan 09, 2018: Ozempic approved in Canada for the treatment of adults with type 2 diabetes 110

Aug 16, 2017: Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 112

Apr 03, 2017: Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment 113

Other Significant Developments 114

Nov 02, 2018: Novo Nordisk to lay off 1,300 employees 114

Aug 08, 2018: Novo Nordisk's operating profit decreased by 8% in danish kroner and increased by 4% in local currencies in the first six months of 2018 115

Mar 16, 2017: CVS Health Launches Reduced Rx Savings Program to Give Patients Access to More Affordable Medications 116

Appendix 117

Methodology 117

About GlobalData 117

Contact Us 117

Disclaimer 117


List Of Figure

List of Figures

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Novo Nordisk AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Novo Nordisk AS, Deals By Therapy Area, 2012 to YTD 2018 11

Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18

Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20

Ossianix and Novo Nordisk Enter into Research and Option Agreement 21

Evotec Enters into Co-Development Agreement with Novo Nordisk 22

Kallyope and Novo Nordisk Enter into Research Agreement 23

BioLamina and Novo Nordisk Enter into Partnership 24

Prime Therapeutics Enters into Contract with Novo Nordisk 25

Metacrine Enters into Agreement with Novo Nordisk 26

Novo Nordisk Enters into Research Agreement with University of Oxford 27

Novo Nordisk Enters into Research Agreement with UW Medicine 28

BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29

Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30

Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31

Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32

Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33

Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34

Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35

Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36

Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37

Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38

Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39

Novo Nordisk Enters Licensing Agreement into with reMYND 40

Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41

Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42

Novo Nordisk Enters into Licensing Agreement with Ablynx 43

Novo Nordisk Enters into Licensing Agreement with Emisphere 44

Novo Nordisk Expands Licensing Agreement with Genmab 45

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46

Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47

Novo Nordisk Amends Licensing Agreement with Emisphere 48

Adimab Enters Into Licensing Agreement With Novo Nordisk 49

Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50

Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51

Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52

Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53

Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55

Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56

Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57

NNIT Prices IPO for USD191 Million 58

Novo Nordisk Plans to Sell Inflammation Business 60

Novo Nordisk May Acquire Global Blood Therapeutics 61

Novo Nordisk to Acquire Calibrium and MB2 62

Novo Nordisk AS, Key Competitors 63

Novo Nordisk AS, Key Employees 64

Novo Nordisk AS, Subsidiaries 65

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Novo Nordisk AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.